1

Cardiovascular Biomarker Testing Market (By Type: Creatine Kinase, Troponins, Myoglobin, Ischemia Modified Albumin, High-sensitivity C-reactive protein (hsCRP), Others; By Disease: Congestive Heart Failure, Acute Coronary Syndrome, Myocardial Infarction, Atherosclerosis, Ischemia; By End-User: Laboratory Testing, Point of Care Testing) – Global Industry Analysis, Market Size, Opportunities and Forecast 2021-2028

Category : Healthcare and Pharmaceuticals | Delivery Format: PDF | Status: Published | Pages : 250

CHAPTER 1. Industry Overview of Cardiovascular Biomarker Testing

1.1. Definition and Scope 

1.1.1. Definition of Cardiovascular Biomarker Testing

1.1.2. Market Segmentation

1.1.3. Years Considered for the Study

1.1.4. Assumptions and Acronyms Used

1.1.4.1. Market Assumptions and Market Forecast

1.1.4.2. Acronyms Used in Global Cardiovascular Biomarker Testing

1.2. Summary

1.2.1. Executive Summary 

1.2.2. Cardiovascular Biomarker Testing By Biomarker Type

1.2.3. Cardiovascular Biomarker Testing By Disease Type

1.2.4. Cardiovascular Biomarker Testing By End-User

1.2.5. Cardiovascular Biomarker Testing by Regions


CHAPTER 2. Research Approach

2.1. Methodology 

2.1.1. Research Programs

2.1.2. Market Size Estimation

2.1.3. Market Breakdown and Data Triangulation

2.2. Data Source

2.2.1. Secondary Sources

2.2.2. Primary Sources


CHAPTER 3. Market Dynamics And Competition Analysis

3.1. Market Drivers

3.1.1. Driver 1

3.1.2. Driver 2

3.2. Restraints and Challenges

3.2.1. Restrain 1

3.2.2. Restrain 2

3.3. Growth Opportunities

3.3.1. Opportunity 1

3.3.2. Opportunity 2 

3.4. Porter’s Five Forces Analysis

3.4.1. Bargaining Power of Suppliers

3.4.2. Bargaining Power of Buyers

3.4.3. Threat of Substitute

3.4.4. Threat of New Entrants

3.4.5. Degree of Competition

3.5. Market Concentration Ratio and Market Maturity Analysis of Cardiovascular Biomarker Testing

3.5.1. Go To Market Strategy

3.5.1.1. Introduction

3.5.1.2. Growth

3.5.1.3. Maturity

3.5.1.4. Saturation

3.5.1.5. Possible Development

3.6. Technological Roadmap for Cardiovascular Biomarker Testing

3.7. Value Chain Analysis

3.7.1. List of Key Manufacturers 

3.7.2. List of Customers

3.7.3. Level of Integration

3.8. Regulatory Compliance

3.9. Competitive Landscape, 2019

3.9.1. Player Positioning Analysis

3.9.2. Key Strategies Adopted By Leading Players


CHAPTER 4. Cardiovascular Biomarker Testing By Biomarker Type

4.1. Introduction

4.2. Cardiovascular Biomarker Testing Revenue By Biomarker Type

4.2.1. Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast, By Biomarker Type, 2017-2028

4.2.2. Creatine Kinase

4.2.2.1. Creatine Kinase Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028

4.2.3. Troponins

4.2.3.1. Troponins Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028

4.2.4. Myoglobin

4.2.4.1. Myoglobin Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028

4.2.5. Ischemia Modified Albumin

4.2.5.1. Ischemia Modified Albumin Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028

4.2.6. High-sensitivity C-reactive protein (hsCRP)

4.2.6.1. High-sensitivity C-reactive protein (hsCRP) Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028

4.2.7. Others

4.2.7.1. Others Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028


CHAPTER 5. Cardiovascular Biomarker Testing Revenue By End-User

5.1. Introduction

5.2. Cardiovascular Biomarker Testing Revenue (US$ Bn) By End-User

5.2.1. Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By End-User, 2017-2028

5.2.2. Laboratory Testing

5.2.2.1. Laboratory Testing Revenue (US$ Bn) and Growth Rate (%), 2017-2028

5.2.3. Point of Care Testing

5.2.3.1. Point of Care Testing Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028


CHAPTER 6. Cardiovascular Biomarker Testing By Disease Type 

6.1. Introduction

6.2. Cardiovascular Biomarker Testing Revenue (US$ Bn) By Disease Type

6.2.1. Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Disease Type, 2017-2028

6.2.2. Congestive Heart Failure

6.2.2.1. Congestive Heart Failure Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028

6.2.3. Acute Coronary Syndrome

6.2.3.1. Acute Coronary Syndrome Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028

6.2.4. Myocardial Infarction

6.2.4.1. Myocardial Infarction Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028

6.2.5. Atherosclerosis

6.2.5.1. Atherosclerosis Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028

6.2.6. Ischemia

6.2.6.1. Ischemia Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028


CHAPTER 7. North America Cardiovascular Biomarker Testing By Country 

7.1. North America Cardiovascular Biomarker Testing Overview

7.2. U.S.

7.2.1. U.S. Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Biomarker Type, 2017-2028

7.2.2. U.S. Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Disease Type, 2017-2028

7.2.3. U.S. Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By End-User, 2017-2028

7.3. Canada

7.3.1. Canada Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Biomarker Type, 2017-2028

7.3.2. Canada Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Disease Type, 2017-2028

7.3.3. Canada Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By End-User, 2017-2028

7.4. North America PEST Analysis


CHAPTER 8. Europe Cardiovascular Biomarker Testing By Country

8.1. Europe Cardiovascular Biomarker Testing Overview

8.2. U.K.

8.2.1. U.K. Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Biomarker Type, 2017-2028

8.2.2. U.K. Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Disease Type, 2017-2028

8.2.3. U.K. Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By End-User, 2017-2028

8.3. Germany

8.3.1. Germany Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Biomarker Type, 2017-2028

8.3.2. Germany Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Disease Type, 2017-2028

8.3.3. Germany Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By End-User, 2017-2028

8.4. France 

8.4.1. France Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Biomarker Type, 2017-2028

8.4.2. France Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Disease Type, 2017-2028

8.4.3. France Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By End-User, 2017-2028

8.5. Spain

8.5.1. Spain Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Biomarker Type, 2017-2028

8.5.2. Spain Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Disease Type, 2017-2028

8.5.3. Spain Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By End-User, 2017-2028

8.6. Rest of Europe

8.6.1. Rest of Europe Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Biomarker Type, 2017-2028

8.6.2. Rest of Europe Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Disease Type, 2017-2028

8.6.3. Rest of Europe Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By End-User, 2017-2028

8.7. Europe PEST Analysis


CHAPTER 9. Asia Pacific Cardiovascular Biomarker Testing By Country

9.1. Asia Pacific Cardiovascular Biomarker Testing Overview

9.2. China

9.2.1. China Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Biomarker Type, 2017-2028

9.2.2. China Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Disease Type, 2017-2028

9.2.3. China Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By End-User, 2017-2028

9.3. Japan

9.3.1. Japan Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Biomarker Type, 2017-2028

9.3.2. Japan Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Disease Type, 2017-2028

9.3.3. Japan Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By End-User, 2017-2028

9.4. India

9.4.1. India Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Biomarker Type, 2017-2028

9.4.2. India Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Disease Type, 2017-2028

9.4.3. India Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By End-User, 2017-2028

9.5. Australia

9.5.1. Australia Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Biomarker Type, 2017-2028

9.5.2. Australia Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Disease Type, 2017-2028

9.5.3. Australia Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By End-User, 2017-2028

9.6. South Korea

9.6.1. South Korea Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Biomarker Type, 2017-2028

9.6.2. South Korea Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Disease Type, 2017-2028

9.6.3. South Korea Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By End-User, 2017-2028

9.7. Rest of Asia-Pacific

9.7.1. Rest of Asia-Pacific Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Biomarker Type, 2017-2028

9.7.2. Rest of Asia-Pacific Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Disease Type, 2017-2028

9.7.3. Rest of Asia-Pacific Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By End-User, 2017-2028

9.8. Asia Pacific PEST Analysis


CHAPTER 10. Latin America Cardiovascular Biomarker Testing By Country

10.1. Latin America Cardiovascular Biomarker Testing Overview

10.2. Brazil

10.2.1. Brazil Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Biomarker Type, 2017-2028

10.2.2. Brazil Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Disease Type, 2017-2028

10.2.3. Brazil Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By End-User, 2017-2028

10.3. Mexico

10.3.1. Mexico Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Biomarker Type, 2017-2028

10.3.2. Mexico Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Disease Type, 2017-2028

10.3.3. Mexico Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By End-User, 2017-2028

10.4. Rest of Latin America

10.4.1. Rest of Latin America Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Biomarker Type, 2017-2028

10.4.2. Rest of Latin America Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Disease Type, 2017-2028

10.4.3. Rest of Latin America Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By End-User, 2017-2028

10.5. Latin America PEST Analysis


CHAPTER 11. Middle East & Africa Cardiovascular Biomarker Testing By Country 

11.1. Middle East & Africa Cardiovascular Biomarker Testing Overview

11.2. GCC

11.2.1. GCC Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Biomarker Type, 2017-2028

11.2.2. GCC Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Disease Type, 2017-2028

11.2.3. GCC Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By End-User, 2017-2028

11.3. South Africa

11.3.1. South Africa Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Biomarker Type, 2017-2028

11.3.2. South Africa Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Disease Type, 2017-2028

11.3.3. South Africa Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By End-User, 2017-2028

11.4. Rest of Middle East & Africa

11.4.1. Rest of Middle East & Africa Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Biomarker Type, 2017-2028

11.4.2. Rest of Middle East & Africa Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Disease Type, 2017-2028

11.4.3. Rest of Middle East & Africa Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By End-User, 2017-2028

11.5. Middle East & Africa PEST Analysis


CHAPTER 12. Player Analysis Of Cardiovascular Biomarker Testing

12.1. Cardiovascular Biomarker Testing Company Share Analysis

12.2. Competition Matrix

12.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment

12.2.2. New Product Launches and Product Enhancements

12.2.3. Mergers And Acquisition In Global Cardiovascular Biomarker Testing

12.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements


CHAPTER 13. COMPANY PROFILE

13.1. Becton, Dickinson and Company

13.1.1. Company Snapshot

13.1.2. Business Overview

13.1.3. Financial Overview

13.1.3.1. Revenue (US$ Bn), 2019

13.1.3.2. Becton, Dickinson and Company 2019 Cardiovascular Biomarker Testing Business Regional Distribution

13.1.4. Product/ Service and Specification

13.1.5. Recent Developments & Business Strategy

13.2. Abbott Laboratories

13.3. Bio-Rad Laboratories, Inc.

13.4. BioMérieux

13.5. F. Hoffmann-La Roche AG

13.6. Danaher Corporation

13.7. Randox Laboratories

13.8. Thermo Fisher Scientific

13.9. Siemens Healthineers

13.10. Others

Cart Summary